Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.46−0.28 (-4.15%)
Close on Nov 20, 2026Market cap $422.40MP/E 40.4Yield –
Arvinas free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Arvinas's free cash flow for the twelve months ending Jun 30, 2026 was -$208.80M. For fiscal 2025 it was -$275.70M. The highest annual figure on record is $554.70M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$275.70M | – |
| FY2024 | Dec 31, 2024 | -$261.10M | – |
| FY2023 | Dec 31, 2023 | -$350.70M | – |
| FY2022 | Dec 31, 2022 | -$280.30M | -150.5% |
| FY2021 | Dec 31, 2021 | $554.70M | – |
| FY2020 | Dec 31, 2020 | -$96.10M | – |
| FY2019 | Dec 31, 2019 | -$46.90M | – |
| FY2018 | Dec 31, 2018 | -$18.95M | -562.1% |
| FY2017 | Dec 31, 2017 | $4.10M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$48.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$70.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$59.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$96.60M | -294.8% |
| Q1 FY2025 | Mar 31, 2025 | -$89.30M | – |
| Q4 FY2024 | Dec 31, 2024 | -$84.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$128.70M | – |
| Q2 FY2024 | Jun 30, 2024 | $49.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$97.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$83.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$85.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$89.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$92.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$72.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$68.80M | -110.1% |
| Q2 FY2022 | Jun 30, 2022 | -$80.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$59.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.60M | – |
| Q3 FY2021 | Sep 30, 2021 | $680.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$47.90M | – |
| Q1 FY2021 | Mar 31, 2021 | -$40.00M | – |
| Q4 FY2020 | Dec 31, 2020 | -$30.77M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.79M | -3674.3% |
| Q2 FY2020 | Jun 30, 2020 | -$23.23M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.31M | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.00M | – |
| Q3 FY2019 | Sep 30, 2019 | $665.60K | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.46M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.11M | -170.3% |
| Q4 FY2018 | Dec 31, 2018 | -$12.88M | -146.4% |
| Q3 FY2018 | Sep 30, 2018 | -$11.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.81M | – |
| Q1 FY2018 | Mar 31, 2018 | $18.66M | – |
| Q4 FY2017 | Dec 31, 2017 | $27.72M | – |
See a number that looks wrong?